Inactive Instrument

Pharmacyclics, Inc. Stock

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

07/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

07/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
22/04/15	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
22/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
09/04/15	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
06/03/15	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
06/03/15	Wall Street closes up slightly ahead of jobs report	RE
06/03/15	AbbVie : CEO says new form of Humira could thwart generics	RE
06/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
02/06/14	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

08/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
08/01/16	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
08/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
08/01/16	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
08/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

06/03/15	Wall Street se reprend un peu dans un climat d'attente
06/03/15	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
05/03/15	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	01/02/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.29%	-0.99%	-1.34%	+11.57%	47.74B
REVOLUTION MEDICINES, INC.	-0.61%	+4.26%	+396.16%	+647.20%	39.98B
BEONE MEDICINES AG	0.00%	+4.93%	+11.81%	+55.56%	36.23B
IQVIA HOLDINGS INC.	+2.48%	+4.57%	+7.05%	-5.05%	35.59B
CELLTRION, INC.	+0.62%	+3.53%	+5.41%	+42.19%	27.91B
MEDPACE HOLDINGS, INC.	-2.00%	+11.64%	+31.71%	+136.81%	16.45B
ASCENDIS PHARMA A/S	-0.17%	+0.66%	-	-	16.71B
EUROFINS SCIENTIFIC SE	+0.57%	-3.39%	+2.87%	+7.99%	13.21B
ICON PUBLIC LIMITED COMPANY	+1.82%	+1.56%	-9.75%	-30.15%	12.93B
Average	+0.34%	+2.77%	+55.49%	+108.26%	27.42B
Weighted average by Cap.	+0.38%	+2.94%	+74.07%	+136.52%

Employees

Sector